Accutar Biotechnology
Accutar Biotechnology Inc. is a clinical-stage biotechnology company headquartered in Cranbury, New Jersey, founded in 2015 and previously based in Brooklyn, New York, with operations in Shanghai. It applies deep learning to small-molecule drug discovery and runs its own oncology pipeline, including the AC0682 and AC0176 protein degraders in Phase 1 trials. Its computational platform is a set of in-house AI products used in its own preclinical workflow and offered to partners: ChemiRise (retrosynthesis), Orbital (neural-network docking), Virtual Screen, Intelligent-SAR, Chemi-Net (ADME prediction) and the PatentOne AI suite (InsightOne, GenusOne). Accutar publishes no developer program: no public API, developer portal, reference documentation, machine-readable specification or SDK exists on any host it operates. Access to the AI products is arranged by email enquiry for a trial or demo.
Accutar Biotechnology is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Artificial Intelligence.
Accutar Biotechnology’s developer surface includes engineering blog and 8 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.